Lavignac C, Volkov L, Massé A, Rigaud M, Frindel E
Faculté de Médecine de Limoges, Laboratoire de Biochimie Médicale, Limoges, France.
Leukemia. 1992 Oct;6(10):1045-7.
AcSDKP is a physiological negative regulator of hematopoietic stem cell proliferation. To investigate the applicability of AcSDKP in the prevention of graft-versus-host disease, this tetrapeptide was tested in mice and showed an inhibitory effect on the mixed lymphocyte reaction (MLR). In this paper we report MLR using human whole blood cells. The maximum inhibitory effect (50%) was obtained at 2.5 ng/ml AcSDKP. All experiments showed a constant dose response. Experiments are now being conducted to elucidate the mechanism of this inhibition.
N-乙酰-Ser-Asp-Lys-Pro(AcSDKP)是造血干细胞增殖的生理性负调节因子。为研究AcSDKP在预防移植物抗宿主病中的适用性,该四肽在小鼠中进行了测试,并对混合淋巴细胞反应(MLR)显示出抑制作用。在本文中,我们报告了使用人全血细胞的MLR。在2.5 ng/ml AcSDKP时获得最大抑制效果(50%)。所有实验均显示出恒定的剂量反应。目前正在进行实验以阐明这种抑制的机制。